Myriad Genetics, Inc. MYGN recently launched a patient home collection kit for its GeneSight Psychotropic test, enabling the DNA sample collection that is generally undergone in a clinician’s ...

Myriad Genetics, Inc. (NASDAQ:MYGN) is making waves at the 2025 ASCO Annual Meeting, presenting seven new research studies that underscore major advances in molecular diagnostics and precision ...

Myriad Genetics (MYGN) continues to empower parents with increased access to prenatal testing. SneakPeek is now available over the counter in more than 8,800 retail locations nationwide.

Top patent court shoots down Myriad gene testing patents Myriad lost at the Supreme Court but kept suing over competing BRCA tests.

He and a colleague proved a theory advanced by the Nobel Prize winners James Watson and Francis Crick, who discovered DNA’s ...

Myriad discloses that FDA asked for changes to GeneSight test Regulators have questioned DNA test for drug effectiveness Source: Getty Images Gift this article ...

In reviewing Myriad’s patent, the Court found the isolated DNA claims as drawn to the genetic code to be the same as native DNA, and it therefore concluded that they fell within the "law of ...

In 2022, Myriad Genetics acquired SneakPeek’s parent company, Gateway Genomics, with a shared goal of expanding consumer access to the innovative at-home fetal sex test through retail partnerships.